Analysts Adjust Forecasts for Sichuan Kelun-Biotech Amid Financial Headwinds
In the wake of a less-than-stellar annual report from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990), financial analysts have revised their outlook on the company, causing a stir in the biopharmaceutical industry. The most recent data points towards an unsettling trend for the company, with losses expected to surge by 32% to CN¥3.15 per share.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
